Blair William & Co. IL Decreases Holdings in Agilent Technologies, Inc. $A

Blair William & Co. IL decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 37.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,743 shares of the medical research company’s stock after selling 13,792 shares during the period. Blair William & Co. IL’s holdings in Agilent Technologies were worth $2,919,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Norges Bank bought a new stake in Agilent Technologies in the second quarter worth $395,088,000. AQR Capital Management LLC boosted its position in Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after buying an additional 1,652,244 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Agilent Technologies by 132.2% during the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after buying an additional 1,340,161 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock worth $1,560,964,000 after buying an additional 1,273,994 shares during the period. Finally, Troy Asset Management Ltd increased its holdings in shares of Agilent Technologies by 74.3% in the second quarter. Troy Asset Management Ltd now owns 2,397,820 shares of the medical research company’s stock worth $282,967,000 after buying an additional 1,021,865 shares during the period. Institutional investors own 87.41% of the company’s stock.

Analyst Ratings Changes

A has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on Agilent Technologies in a report on Tuesday, December 9th. They set a “buy” rating and a $170.00 target price for the company. UBS Group decreased their price target on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wells Fargo & Company lowered their price objective on Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating for the company in a research report on Thursday, February 26th. Weiss Ratings reissued a “hold (c+)” rating on shares of Agilent Technologies in a research note on Monday, December 29th. Finally, Citigroup raised their target price on shares of Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $161.20.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent agreed to acquire Biocare Medical for about $950 million — a bolt-on that strengthens its immunohistochemistry/diagnostics consumables and pathology market exposure, adding recurring reagents and slide/staining workflow products that can lift revenue durability and margin profile over time. Agilent to acquire Biocare in $950M ‘complementary combination’
• Positive Sentiment: Agilent launched “Agilent Advanced Therapeutics,” unifying its CDMO capabilities across the U.S. and Canada — a move aimed at scaling drug-development and manufacturing services that can generate higher-margin service revenue and cross-sell opportunities with instrument/consumable customers. Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
• Neutral Sentiment: Citi opened a 90‑day “upside catalyst” watch on Agilent as part of a sector sweep — this flags potential positive catalysts but is not a formal upgrade; it signals analysts are watching for near‑term drivers rather than changing the fundamental view. Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
• Neutral Sentiment: Coverage noting “steady growth amid headwinds” emphasizes Agilent’s resilient top-line and reiterated FY26 guidance but highlights macro and sector pressures that could keep near-term multiples constrained. Agilent Technologies Signals Steady Growth Amid Headwinds
• Neutral Sentiment: Analysis pieces point out Agilent has recently underperformed the S&P 500 despite analyst optimism — a reminder that valuation and sector rotation dynamics could limit near-term upside. Is Agilent Technologies Stock Underperforming the S&P 500?
• Negative Sentiment: High-profile negative commentary from Jim Cramer — saying investors “don’t need” the stock — may pressure retail sentiment and contribute to short-term volatility despite the company’s strategic moves. Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”

Agilent Technologies Trading Up 0.0%

Shares of A opened at $115.44 on Thursday. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $160.27. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $131.36 and its 200-day moving average price is $135.93. The firm has a market capitalization of $32.62 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 2.43 and a beta of 1.31.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The company had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. During the same period in the previous year, the company earned $1.31 earnings per share. Agilent Technologies’s quarterly revenue was up 7.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be given a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 annualized dividend and a dividend yield of 0.9%. Agilent Technologies’s dividend payout ratio is currently 22.52%.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.